Kodiak Sciences Statistics
Total Valuation
Kodiak Sciences has a market cap or net worth of $1.66 billion. The enterprise value is $1.65 billion.
Important Dates
The next estimated earnings date is Thursday, March 26, 2026, after market close.
| Earnings Date | Mar 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kodiak Sciences has 61.97 million shares outstanding. The number of shares has increased by 0.42% in one year.
| Current Share Class | 61.97M |
| Shares Outstanding | 61.97M |
| Shares Change (YoY) | +0.42% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 4.59% |
| Owned by Institutions (%) | 60.95% |
| Float | 39.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 59.81 |
| P/TBV Ratio | 70.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.78, with a Debt / Equity ratio of 2.63.
| Current Ratio | 1.78 |
| Quick Ratio | 1.70 |
| Debt / Equity | 2.63 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -207.92% and return on invested capital (ROIC) is -80.91%.
| Return on Equity (ROE) | -207.92% |
| Return on Assets (ROA) | -47.21% |
| Return on Invested Capital (ROIC) | -80.91% |
| Return on Capital Employed (ROCE) | -127.03% |
| Weighted Average Cost of Capital (WACC) | 18.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.77M |
| Employee Count | 123 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +547.34% in the last 52 weeks. The beta is 2.65, so Kodiak Sciences's price volatility has been higher than the market average.
| Beta (5Y) | 2.65 |
| 52-Week Price Change | +547.34% |
| 50-Day Moving Average | 25.98 |
| 200-Day Moving Average | 14.90 |
| Relative Strength Index (RSI) | 55.12 |
| Average Volume (20 Days) | 691,530 |
Short Selling Information
The latest short interest is 7.32 million, so 11.81% of the outstanding shares have been sold short.
| Short Interest | 7.32M |
| Short Previous Month | 7.13M |
| Short % of Shares Out | 11.81% |
| Short % of Float | 18.70% |
| Short Ratio (days to cover) | 8.96 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -223.11M |
| Pretax Income | -217.34M |
| Net Income | -217.34M |
| EBITDA | -204.70M |
| EBIT | -223.11M |
| Earnings Per Share (EPS) | -$4.12 |
Full Income Statement Balance Sheet
The company has $72.04 million in cash and $62.20 million in debt, with a net cash position of $9.84 million or $0.16 per share.
| Cash & Cash Equivalents | 72.04M |
| Total Debt | 62.20M |
| Net Cash | 9.84M |
| Net Cash Per Share | $0.16 |
| Equity (Book Value) | 23.69M |
| Book Value Per Share | 0.45 |
| Working Capital | 33.30M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$126.70 million and capital expenditures -$587,000, giving a free cash flow of -$127.29 million.
| Operating Cash Flow | -126.70M |
| Capital Expenditures | -587,000 |
| Free Cash Flow | -127.29M |
| FCF Per Share | -$2.05 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kodiak Sciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.42% |
| Shareholder Yield | -0.42% |
| Earnings Yield | -13.09% |
| FCF Yield | -7.66% |
Analyst Forecast
The average price target for Kodiak Sciences is $28.29, which is 5.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $28.29 |
| Price Target Difference | 5.56% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |